Triple negative is the biggest out of the 4 her2 expressing breast cancers again you are wrong there are many front line treatments for 1+, 2+ and of course where Herceptin lives 3+ so the revenues and value are split amongst those 3, where triple negative there is zero treatments other then cut it out and then factor in the enhancement from the PD1 inhibitor which adds huge value. Plus since 2011/2012 breast cancer counts have gone up significantly like cervical cancer that up to last year was an orphan indication but not any more, so patient pops are much higher, pd1 inhibitor, triple negative where you get them all, I’d say it’s the same if not more valuable since 11.